Powder: -20°C for 3 years | In solvent: -80°C for 1 year
N-Acetyl-D-galactosamine (GalNAc) 是一种源自半乳糖的末端必需氨基糖,在人体中形成 A 型血的抗原。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 126 | 现货 | ||
5 mg | ¥ 245 | 现货 | ||
10 mg | ¥ 342 | 现货 | ||
25 mg | ¥ 583 | 现货 | ||
50 mg | ¥ 875 | 现货 | ||
100 mg | ¥ 1,310 | 现货 | ||
200 mg | ¥ 1,960 | 现货 |
产品描述 | N-Acetyl-D-galactosamine (GalNAc) is a terminal essential amino sugar derived from galactose and forms the antigens of blood group A in humans. |
体外活性 | N-Acetyl-D-galactosamine (GalNAc or D-GalNAc) on the damage induced by SBA on the membrane permeability and tight junction proteins of piglet intestinal epithelium (IPEC-J2) cells. The IPEC-J2 cells were pre-cultured with 0, 0.125 × 10-4 , 0.25 × 10-4 , 0.5 × 10-4 , 1.0 × 10-4 and 2.0 × 10-4 mmol/L GalNAc at different time period (1, 2, 4 and 8 hr) before being exposed to 0.5 mg/ml SBA for 24 hr.Pre-incubation with GalNAc mitigates the mechanical barrier injury as reflected by a significant increase in trans-epithelial electric resistance (TEER) value and a decrease in alkaline phosphatase (ALP) activity in cell culture medium pre-treated with GalNAc before incubation with SBA as both indicate a reduction in cellular membrane permeability. In addition, mRNA levels of the tight junction proteins occludin and claudin-3 were lower in the SBA-treated groups without pre-treatment with GalNAc. The mRNA expression of occludin was reduced by 17.3% and claudin-3 by 42% (p < 0.01). Moreover, the corresponding protein expression levels were lowered by 17.8% and 43.5% (p < 0.05) respectively. However, in the GalNAc pre-treated groups, occludin and claudin-3 mRNAs were reduced by 1.6% (p > 0.05) and 2.7% (p < 0.01), respectively, while the corresponding proteins were reduced by 4.3% and 7.2% (p < 0.05). In conclusion, GalNAc may prevent the effect of SBA on membrane permeability and tight junction proteins on IPEC-J2s. |
别名 | GalNAc, 2-乙酰胺基-2-脱氧-D-半乳糖 |
分子量 | 221.21 |
分子式 | C8H15NO6 |
CAS No. | 14215-68-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 125 mg/mL (565.07 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O | 1 mM | 4.5206 mL | 22.603 mL | 45.2059 mL | 113.0148 mL |
5 mM | 0.9041 mL | 4.5206 mL | 9.0412 mL | 22.603 mL | |
10 mM | 0.4521 mL | 2.2603 mL | 4.5206 mL | 11.3015 mL | |
20 mM | 0.226 mL | 1.1301 mL | 2.2603 mL | 5.6507 mL | |
50 mM | 0.0904 mL | 0.4521 mL | 0.9041 mL | 2.2603 mL | |
100 mM | 0.0452 mL | 0.226 mL | 0.4521 mL | 1.1301 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
N-Acetyl-D-galactosamine 14215-68-0 Others GalNAc 2-乙酰胺基-2-脱氧-D-半乳糖 NAcetylDgalactosamine N Acetyl D galactosamine Inhibitor inhibitor inhibit